Authors:
- Focuses on important decision points and evidence needed for making decisions at these points during the development of a new drug
- Takes a holistic approach towards drug development by incorporating knowledge learned from the earlier part of the development explicitly into the decisions at later stages
- Shows the parallel between clinical trials and diagnostic tests and how this analogy is used to emphasize the importance of replication in drug development
- Describes how to incorporate prior knowledge into study design and decision making at different stages of drug development
- Explains metrics useful to address the objectives of the different stages of drug development and how to compare design options based on these metrics
- Demonstrates why over-estimation is a common problem in drug development and how adjustment should be considered to correct the over-estimation
Part of the book series: Springer Series in Pharmaceutical Statistics (SSPS)
Buy it now
Buying options
Tax calculation will be finalised at checkout
Other ways to access
This is a preview of subscription content, log in via an institution to check for access.
Table of contents (13 chapters)
-
Front Matter
-
Back Matter
About this book
This book offers a high-level treatise of evidence-based decisions in drug development. Because of the inseparable relationship between designs and decisions, a good portion of this book is devoted to the design of clinical trials. The book begins with an overview of product development and regulatory approval pathways. It then discusses how to incorporate prior knowledge into study design and decision making at different stages of drug development. The latter include selecting appropriate metrics to formulate decisions criteria, determining go/no-go decisions for progressing a drug candidate to the next stage and predicting the effectiveness of a product. Lastly, it points out common mistakes made by drug developers under the current drug-development paradigm.
The book offers useful insights to statisticians, clinicians, regulatory affairs managers and decision-makers in the pharmaceutical industry who have a basic understanding of the drug-development processand the clinical trials conducted to support drug-marketing authorization.
The authors provide software codes for select analytical approaches discussed in the book. The book includes enough technical details to allow statisticians to replicate the quantitative illustrations so that they can generate information to facilitate decision-making themselves.
Reviews
“It is presented in a concise, structured, friendly, and illustrative way that allows for a good understanding of the underlying ideas … . the book from Chuang-Stein and Kirby is a valuable, interesting and easy read for statisticians and clinicians with some methodological background who are involved in clinical development or drug approval and who are looking for a structured way to make clinical development decisions.” (Norbert Benda, Biometrical Journal, Vol. 61 (4), July, 2016)
Authors and Affiliations
-
Kalamazoo, USA
Christy Chuang-Stein
-
Pfizer Statistical Research & Consulting Center, Cambridge, United Kingdom
Simon Kirby
About the authors
Christy Chuang-Stein was Vice President and Head of the Statistical Research and Consulting Center at Pfizer prior to retirement from the company in July 2015. She has more than 30 years of experience in the pharmaceutical industry and 160 scientific publications. She is a Fellow of the American Statistical Association (ASA) and received ASA’s Founders’ Award in 2012. She was the recipient of the Distinguished Achievement Award of the International Chinese Statistical Association in 2013.
Simon Kirby is Senior Director at the Statistical Research and Consulting Center at Pfizer. He has worked for Pfizer for more than 17 years after previously holding the position of Principal Lecturer in Statistics at Liverpool John Moores University. He has also previously worked as a Statistician at the Institute of Food Research in the UK, Rothamsted and Revlon Healthcare.
Bibliographic Information
Book Title: Quantitative Decisions in Drug Development
Authors: Christy Chuang-Stein, Simon Kirby
Series Title: Springer Series in Pharmaceutical Statistics
DOI: https://doi.org/10.1007/978-3-319-46076-5
Publisher: Springer Cham
eBook Packages: Mathematics and Statistics, Mathematics and Statistics (R0)
Copyright Information: Springer International Publishing AG 2017
Softcover ISBN: 978-3-319-83434-4Published: 28 July 2018
eBook ISBN: 978-3-319-46076-5Published: 25 May 2017
Series ISSN: 2366-8695
Series E-ISSN: 2366-8709
Edition Number: 1
Number of Pages: XV, 248
Number of Illustrations: 16 b/w illustrations, 11 illustrations in colour
Topics: Statistics for Life Sciences, Medicine, Health Sciences, Biostatistics, Drug Safety and Pharmacovigilance, Pharmaceutical Sciences/Technology, Quality Control, Reliability, Safety and Risk